Anixa Biosciences to Detail Ovarian CAR-T Dose Escalation Approval and Positive Breast Vaccine Data
Anixa Biosciences will host a virtual annual meeting on March 10 to review regulatory approval for dose escalation in its Phase 1 ovarian cancer CAR-T trial. Final Phase 1 breast cancer vaccine data met primary endpoints, showed favorable tolerability and induced protocol-defined immune responses in most participants.
1. Meeting Overview
Anixa Biosciences will hold its 2026 annual meeting of stockholders on March 10 at 10:00 a.m. PT in a virtual format open to all interested parties. CEO Dr. Amit Kumar will present a corporate update and host a live Q&A session following formal business and voting items.
2. Ovarian CAR-T Trial Progress
The company will review encouraging survival observations from its ongoing Phase 1 ovarian cancer CAR-T trial and discuss regulatory approval granted for substantial dose escalation, leveraging its novel CER-T technology collaboration with Moffitt Cancer Center.
3. Breast Vaccine Phase 1 Results
Anixa will also present final Phase 1 data from its breast cancer vaccine program, which met all primary endpoints, demonstrated favorable tolerability and induced protocol-defined immune responses in the majority of participants.